Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › TN › Knoxville › NPI 1699858373
Lab

Laboratory Corporation of America

Laboratory Corporation of America was paid $19.76M by Medicaid between Jan 2018 and Dec 2024, across 308 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 12% of everything it billed.

33Billing provider infoLABORATORY CORPORATION OF AMERICA
KNOXVILLE, TN 37920
33aNPI1699858373assigned 10/24/2006
33bProvider typeClinical Medical Laboratory
28Total paid$19.76M
24GClaims3,294,873
24DCodes billed308
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Tennessee

Rank by total paid#6 of 70
Median peer was paid$141K
This provider vs. median140×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018309,131$1.70M
2019373,787$1.60M
2020392,198$2.27M
2021507,216$3.51M
2022611,977$3.22M
2023591,283$3.97M
2024incomplete509,281$3.49M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 12% 33,166 29,212 $2.31M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 9.1% 6,680 5,205 $1.81M
80050 General health panel 7.2% 99,281 82,816 $1.42M
80061 Lipid panel 3.7% 232,967 193,748 $741K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 3.7% 25,577 19,703 $729K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 3.6% 99,078 76,017 $703K
80053 Comprehensive metabolic panel 3.1% 254,606 212,491 $619K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 3.1% 3,111 2,393 $605K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2.9% 220,061 180,430 $582K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 2.3% 43,110 34,985 $458K
84443 Thyroid stimulating hormone (TSH) 2.3% 143,609 116,683 $457K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 1.9% 30,350 24,813 $384K
296 more codes
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 1.9% 30,261 $381K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 1.8% 34,290 $355K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 1.6% 15,403 $311K
83036 Hemoglobin; glycosylated (A1C) 1.6% 157,150 $310K
87086 Culture, bacterial; quantitative colony count, urine 1.5% 134,739 $298K
80081 1.5% 13,366 $295K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1.4% 7,569 $282K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.4% 21,668 $282K
36415 Collection of venous blood by venipuncture 1.3% 114,938 $251K
80055 1.2% 6,577 $245K
82607 1.2% 66,321 $227K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 1.1% 3,848 $226K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 1.0% 3,652 $204K
86803 <1% 34,957 $175K
84439 <1% 77,373 $165K
80074 <1% 15,477 $147K
82746 <1% 42,085 $138K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 5,721 $137K
82728 <1% 39,412 $111K
86235 <1% 3,756 $111K
87186 <1% 40,170 $105K
84403 <1% 14,206 $105K
87070 <1% 34,321 $100K
84702 <1% 16,169 $95K
87150 <1% 7,074 $94K
83880 <1% 10,759 $88K
83970 <1% 11,769 $88K
83550 <1% 47,740 $85K
87088 <1% 38,048 $84K
86480 <1% 4,231 $83K
87077 <1% 33,624 $82K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 3,428 $81K
86003 <1% 4,048 $80K
86850 <1% 14,268 $78K
81329 <1% 2,511 $78K
87081 <1% 25,601 $72K
84153 <1% 19,738 $69K
83540 <1% 52,162 $69K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 9,111 $68K
80048 Basic metabolic panel (calcium, ionized) <1% 35,798 $64K
82570 <1% 37,149 $61K
87522 Neg quan hep c or qual rna <1% 4,965 $60K
82670 <1% 6,262 $60K
83001 <1% 8,951 $60K
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 1,160 $57K
84144 <1% 7,437 $56K
82950 <1% 21,026 $55K
82951 <1% 7,331 $53K
83735 <1% 26,035 $51K
0099U <1% 553 $49K
84402 <1% 6,793 $49K
83002 <1% 7,344 $49K
85027 <1% 24,623 $47K
86376 <1% 11,239 $46K
86038 <1% 12,852 $43K
87902 <1% 542 $42K
84436 <1% 27,049 $42K
84481 <1% 8,819 $41K
86696 <1% 5,780 $40K
84146 <1% 6,039 $39K
84480 <1% 10,729 $39K
87340 <1% 11,513 $37K
81001 <1% 30,148 $36K
86140 <1% 24,584 $36K
83525 <1% 8,631 $36K
82784 <1% 5,897 $36K
81257 <1% 584 $34K
87507 <1% 558 $34K
84479 <1% 21,221 $32K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 2,619 $32K
82043 <1% 31,501 $31K
84550 <1% 24,181 $30K
83690 <1% 11,208 $30K
86762 <1% 5,714 $30K
86769 <1% 840 $26K
82248 <1% 11,440 $26K
82565 <1% 11,605 $26K
85652 <1% 23,340 $26K
82785 <1% 4,729 $25K
85730 <1% 9,288 $24K
85610 <1% 14,555 $24K
86592 <1% 15,759 $24K
82150 <1% 9,214 $22K
84425 <1% 4,003 $22K
80076 <1% 7,353 $22K
84520 <1% 11,304 $21K
84460 <1% 10,417 $20K
83615 <1% 8,431 $20K
88112 <1% 2,618 $20K
84450 <1% 10,484 $20K
82247 <1% 7,848 $19K
86665 <1% 1,569 $19K
86800 <1% 3,576 $18K
84156 <1% 15,344 $18K
86200 <1% 4,585 $17K
86431 <1% 10,188 $17K
86160 <1% 2,740 $16K
87075 <1% 5,079 $15K
87486 <1% 1,354 $15K
87581 <1% 1,354 $15K
84681 <1% 2,780 $14K
86706 <1% 4,475 $14K
87625 <1% 811 $14K
86225 <1% 3,760 $14K
82627 <1% 1,663 $13K
82747 <1% 3,330 $13K
81243 <1% 1,995 $13K
84630 <1% 4,095 $12K
86677 <1% 2,119 $12K
83721 <1% 5,344 $11K
82550 <1% 5,140 $11K
82105 <1% 2,725 $11K
82947 <1% 6,266 $11K
82533 <1% 2,218 $11K
84100 <1% 10,431 $10K
86704 <1% 2,888 $10K
86900 <1% 6,338 $10K
86901 <1% 6,320 $10K
81361 <1% 585 $10K
88142 <1% 1,272 $9K
86695 <1% 2,151 $9K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 187 $9K
80164 <1% 3,090 $9K
83516 <1% 1,509 $9K
82977 <1% 5,747 $9K
83655 <1% 1,314 $9K
82672 <1% 1,234 $8K
85045 <1% 7,920 $8K
84703 <1% 1,741 $7K
86593 <1% 4,268 $7K
86008 <1% 1,831 $7K
80051 <1% 2,242 $7K
82952 <1% 3,941 $7K
82140 <1% 1,379 $6K
81255 <1% 584 $6K
85018 <1% 4,952 $6K
86757 <1% 551 $6K
86664 <1% 1,160 $6K
81251 <1% 584 $6K
87427 <1% 1,750 $6K
86618 <1% 890 $5K
84155 <1% 4,175 $5K
80177 <1% 2,033 $5K
86364 <1% 775 $5K
84295 <1% 2,922 $5K
82575 <1% 1,144 $5K
87046 <1% 1,753 $5K
86870 <1% 282 $5K
84075 <1% 4,623 $5K
87045 <1% 1,750 $5K
81200 <1% 584 $5K
85379 <1% 1,219 $5K
82310 <1% 3,827 $4K
82677 <1% 384 $4K
82040 <1% 4,029 $4K
80185 <1% 1,743 $4K
81330 <1% 584 $4K
87521 Neg quan hep c or qual rna <1% 415 $4K
82340 <1% 1,900 $4K
84165 <1% 2,008 $4K
87209 <1% 807 $4K
82465 <1% 2,066 $3K
86360 <1% 271 $3K
82103 <1% 788 $3K
80069 <1% 2,339 $3K
84466 <1% 882 $3K
82330 <1% 1,197 $3K
81003 <1% 3,415 $3K
87529 <1% 250 $3K
83013 <1% 128 $3K
82435 <1% 2,759 $3K
0097U <1% 69 $3K
86705 <1% 745 $3K
86147 <1% 87 $3K
86334 <1% 728 $3K
81290 <1% 583 $3K
81260 <1% 583 $3K
86336 <1% 370 $3K
82652 <1% 313 $3K
81377 <1% 27 $3K
81242 <1% 585 $2K
80197 <1% 1,124 $2K
80178 <1% 1,450 $2K
84132 <1% 1,632 $2K
86037 <1% 294 $2K
81209 <1% 584 $2K
86317 <1% 419 $2K
85014 <1% 2,040 $2K
81401 <1% 442 $2K
84478 <1% 1,387 $2K
82374 <1% 1,946 $2K
86617 <1% 199 $2K
86708 <1% 603 $2K
86231 <1% 334 $2K
86141 <1% 712 $2K
87536 <1% 74 $2K
86787 <1% 404 $2K
86015 <1% 398 $2K
82107 <1% 89 $2K
87177 <1% 819 $2K
84445 <1% 129 $2K
84134 <1% 479 $2K
82085 <1% 516 $2K
86663 <1% 351 $1K
84154 <1% 514 $1K
86258 <1% 270 $1K
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 1,146 $1K
86256 <1% 264 $1K
84484 <1% 341 $1K
86381 <1% 149 $1K
84590 <1% 446 $1K
86308 <1% 410 $1K
81374 <1% 51 $1K
82104 <1% 226 $1K
86666 <1% 131 $1K
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 1,043 $1K
86335 <1% 196 $994.14
87350 <1% 288 $969.65
84446 <1% 287 $905.80
87799 <1% 65 $845.35
80156 <1% 424 $828.95
86671 <1% 171 $828.16
82390 <1% 196 $823.60
84166 <1% 252 $756.71
86780 <1% 130 $729.23
82378 <1% 218 $729.13
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 6,740 $702.96
85007 <1% 716 $663.85
81596 <1% 101 $663.28
87279 <1% 223 $652.67
87276 <1% 223 $652.45
87260 <1% 223 $651.71
87280 <1% 223 $651.71
87275 <1% 223 $651.70
G0475 Hiv antigen/antibody, combination assay, screening <1% 917 $593.40
80175 <1% 253 $585.40
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 18 $564.86
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 2,301 $556.28
86304 <1% 83 $554.53
87184 <1% 208 $548.23
82024 <1% 45 $545.48
83010 <1% 131 $461.54
86753 <1% 46 $446.44
82668 <1% 102 $397.10
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 23 $371.18
82239 <1% 68 $369.93
83921 <1% 62 $343.71
86645 <1% 49 $325.23
86765 <1% 98 $306.78
83883 <1% 93 $297.13
85004 <1% 148 $296.28
86735 <1% 83 $282.10
84080 <1% 90 $281.65
82525 <1% 104 $276.11
81015 <1% 309 $274.66
87205 <1% 154 $271.92
83695 <1% 105 $254.68
86698 <1% 48 $246.47
86060 <1% 99 $233.83
86036 <1% 72 $212.62
84482 <1% 72 $211.25
84207 <1% 37 $209.45
83520 <1% 33 $206.76
83021 <1% 29 $193.92
86300 <1% 40 $191.87
82553 <1% 42 $188.97
86747 <1% 12 $174.00
85048 <1% 197 $159.70
84410 <1% 12 $155.56
83498 <1% 14 $154.65
85049 <1% 112 $149.20
85613 <1% 29 $149.17
86709 <1% 50 $146.45
80184 <1% 95 $146.39
85732 <1% 29 $143.83
87076 <1% 65 $121.97
83527 <1% 37 $110.66
85660 <1% 30 $94.20
84597 <1% 29 $85.66
84270 <1% 15 $82.05
83521 <1% 16 $75.12
87324 <1% 33 $69.24
85060 <1% 12 $59.40
G0307 Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) <1% 53 $58.83
82180 <1% 17 $44.66
85041 <1% 32 $43.76
83090 <1% 17 $35.34
89055 <1% 41 $30.98
83935 <1% 18 $27.65
82172 <1% 35 $24.96
84432 <1% 13 $22.92
S3600 Stat laboratory request (situations other than s3601) <1% 772 $5.47
84300 <1% 13 $2.68
36416 <1% 1,025 $2.36
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision 0% 16 $0.00
88141 0% 46 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILLIAMS, KIMBERLY (VP)
Same official

Other billing entities under WILLIAMS, KIMBERLY

Full network →
ProviderLocationPaid
Laboratory Corporation of America HoldingsBurlington, NC$1.44B
Laboratory Corporation of America HoldingsRaritan, NJ$717.47M
Laboratory Corporation of America HoldingsDublin, OH$617.02M
Laboratory Corporation of America HoldingsBirmingham, AL$289.12M
Laboratory Corporation of AmericaPhoenix, AZ$265.90M
Laboratory Corporation of America HoldingsBurlington, NC$264.26M
Laboratory Corporation of America HoldingsCharleston, WV$220.04M
Laboratory Corporation of AmericaSeattle, WA$186.69M
Laboratory Corporation of AmericaTampa, FL$171.13M
Laboratory Corporation of AmericaSan Diego, CA$147.14M
Laboratory Corporation of AmericaHouston, TX$103.81M
Laboratory Corporation of AmericaEnglewood, CO$77.80M
Laboratory Corporation of AmericaDallas, TX$77.42M
Laboratory Corporation of AmericaBurlington, NC$59.75M
Medtox Laboratories, INCSaint Paul, MN$47.72M
Laboratory Corporation of America HoldingsBurlington, NC$15.65M
Laboratory Corporation of AmericaSan Antonio, TX$11.67M
Tri-Cities Laboratory, LLCKennewick, WA$8.69M
Laboratory Corporation of America HoldingsMonroe, LA$3.39M
Laboratory Corporation of AmericaItasca, IL$3.37M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.